New resources from the Partnership for the U.S. Life Science Ecosystem (PULSE) highlight the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry.
Life sciences M&A represents a critical pathway for companies of all sizes to be able to unlock the resources, expertise and funding they need to bring new treatments and cures to patients. Policymakers can play an important role in supporting these pro-competitive partnerships, which in turn help preserve America’s role as a global leader in life sciences innovation.
Learn more by reading PULSE’s Backgrounder and Myths vs. Facts Issue Brief resources below:
PULSE Backgrounder – Life Sciences M&A: Facilitating Innovation and Fueling Competition
Pro-innovation M&A is a fundamental component of the world-class American life sciences industry and has helped establish America as a global leader in developing new treatments and cures for patients. Supporting pro-competitive life sciences M&A is critical to maintain this leadership and drive continued innovation, competition and growth across the industry. CLICK HERE TO READ THE BACKGROUNDER.
PULSE Issue Brief – Life Sciences M&A: Myths vs. Facts
It is important to understand the unique reality of how M&A works in America’s life sciences industry. Life sciences M&A is fundamentally about improving companies’ chances of successfully completing the long and costly journey to bring a new therapy to patients. M&A helps life sciences companies of all sizes specialize in what they do best and partner when it makes sense. CLICK HERE TO READ THE ISSUE BRIEF.
As these new resources underscore, policymakers must acknowledge the vital role of M&A in fueling American life sciences innovation and avoid creating unnecessary barriers for these pro-competitive collaborations among companies of all sizes.